mProX™ Human NPM1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX406	Magic™ Human NPM1-ALK in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;K562

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Acute Myeloid Leukaemia With Myelodysplasia-Related Features; Leukemia, Acute Myeloid

Gene ID

Human:4869

UniProt ID

Human:P06748

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NPM1 is a gene that is frequently mutated in acute myeloid leukemia (AML). It is associated with specific histopathologic findings in AML, such as the presence of folded or indented nuclei. These morphological features can aid in identifying a molecular subtype of AML called leukemia cutis. Additionally, NPM1 mutations, along with other genetic alterations like FLT3-ITD and KMT2A rearrangements, are associated with rapid disease progression in AML. Immune surveillance of AML, including leukemia stem and progenitor cells, is mediated by HLA-presented antigens on these cells. The identification and validation of these antigens, including those derived from NPM1 and IDH2 mutations, can potentially enable the development of T cell-based immunotherapeutic approaches for AML. Lastly, small molecule inhibitors like NSC348884 have been found to have inhibitory and proapoptotic effects on both wild-type and NPM1-mutated AML cells, with a stronger effect observed in cells carrying the NPM1 mutation.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NPM1 Stable Cell Line (S01YF-1023-PY31). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

What is the significance of NPM1 mutations in acute myeloid leukemia (AML)? Dec 23 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

NPM1 mutations play a crucial role in the development of AML, affecting molecular and cellular mechanisms, diagnostics, prognostics, and therapeutic approaches for patients with NPM1-mutated AML. Dec 23 2020

chat Casey Miller (Verified Customer)

How common are NPM1 mutations in adult acute myeloid leukemia? Jan 02 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

NPM1 mutations are the most common genetic alteration in adult AML, detected in about 30-35% of cases and over 50% of AML with a normal karyotype. Jan 02 2020

Published Data

Fig.1 The effects of NPM1 gene silencing on K562 cell proliferation.

Cell proliferation was assessed using the MTT assay, with OD values measured at 0, 24, 48, and 72 hours at 490 nm. Application of pNPM1-shRNA to K562 cells displayed time-dependent growth inhibition, and results are presented as means ± SD from three replicates (*p<0.05).

Ref: Qin, Feng-Xian, et al. "Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line." International Journal of Medical Sciences 8.4 (2011): 287.

Pubmed: 21537492

DOI: 10.7150/ijms.8.287

Research Highlights

Han, Shannon. et al. "Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations." Journal of cutaneous pathology, 2023.
Leukemia cutis, a term used to describe cutaneous manifestations of leukemic infiltration of the skin, is associated with a poor prognosis. Hematopoietic/lymphoid tumors can involve the skin before, at the same time, or after the initial diagnosis. An early assessment by dermatologists and timely biopsies are crucial for a prompt diagnosis. Previous studies have shown a correlation between cup-like nuclear morphology and concurrent NPM1 and FLT3-ITD mutations in acute myeloid leukemia. In this case report of a 63-year-old female with AML and these mutations, scattered folded or indented nuclei are observed in the cutaneous tissue sections, potentially aiding in identifying this molecular subtype of leukemia cutis.
Han, Shannon. et al. "Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations." Journal of cutaneous pathology, 2023.
Pubmed: 37866827 DOI: 10.1111/cup.14549

Kwon, Adelaide; K, Olga. "Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes." Clinics in laboratory medicine, 2023.
Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) is a progressive increase in blasts due to impaired maturation of the malignant clone, suggesting that MDS and AML form a biological continuum rather than distinct diseases. New research indicates that NPM1 mutations and KMT2A rearrangements are also AML-defining genetic alterations, leading to rapid disease progression, even with <20% blasts. Treatment of patients in this MDS/AML group may ultimately be determined by genetic, biological, and patient-related factors rather than solely the blast percentage.
Kwon, Adelaide; K, Olga. "Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes." Clinics in laboratory medicine, 2023.
Pubmed: 37865509 DOI: 10.1016/j.cll.2023.07.001